MedPath

Phase 1 study to examine the safety and dose-dependent effect of rapamycin topical medicine on perspiration in healthy volunteers

Phase 1
Recruiting
Conditions
hyperhidrosis
Registration Number
JPRN-UMIN000016525
Lead Sponsor
Department of Dermatology Graduate School of Medicine, Osaka University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
12
Inclusion Criteria

Not provided

Exclusion Criteria

1) A person who cannot carry out this treatment plan. 2) A person who have allergy to macrolide antibiotics. 3) A person who received oral administration of rapamycin or RAD001 within 12 months prior to the study entry. 4) A person who received topical administration of rapamycin or RAD001 within three days prior to the study entry. 5) A person who received topical treatment of aluminum chloride or iontophoresis within one months prior to the study entry. 6) A person who received local injection of Botox within three months prior to the study entry. 7) A person who received sympathectomy within 12 months prior to the study entry. 8) A person during pregnancy or lactation 9) A person who cannot undergo QSART and starch-iodine test 10) A person who were judged unsuitable for this study by the investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath